Michael Campbell

Dr Michael Campbell

Dr Michael Campbell

Section Leader, Chemistry
Centre for Drug Candidate Optimisation (CDCO)
Tel: +61 3 990 39528
Email: Michael.campbell@monash.edu
ROPES
LinkedIn
CDCO Website

Biography:

Michael Campbell leads the Chemistry section at the Centre for Drug Candidate Optimisation (CDCO). He joined the CDCO in 2003 with over twenty years' experience in the fields of medicinal chemistry, analytical chemistry and pharmaceutical science. Michael completed his Ph.D. in Medicinal Chemistry at  the University of Melbourne. His role at the CDCO involves leading a team responsible for the physicochemical profiling of new chemical entities to determine their suitability as potential drug candidates. He enjoys being involved in the multi-disciplinary, collaborative research environment of the CDCO.  In addition to experimental investigations, Michael is involved in the general data management of the CDCO and the implementation of cheminformatics techniques across the research group.

Publications

Baragaña, B., Hallyburton, I., Lee, M. C. S., Norcross, N. R., Grimaldi, R., Otto, T. D., Proto, W. R., Blagborough, A. M., Meister, S., Wirjanata, G., Ruecker, A., Upton, L. M., Abraham, T. S., Almeida, M. J., Pradhan, A., Porzelle, A., Martínez, M. S., Bolscher, J. M., Woodland, A., Norval, S., Zuccotto,  F., Thomas, J., Simeons, F., Stojanovski, L., Osuna-Cabello, M., Brock, P. M., Churcher, T. S., Sala, K. A., Zakutansky, S. A., Jiménez-Díaz, M. B., Sanz, L. M., Riley, J., Basak, R., Campbell, M., Avery, V. M., Sauerwein, R. W., Dechering, K. J., Noviyanti, R., Campo, B., Frearson, J. A., Angulo-Barturen,  I., Ferrer-Bazaga, S., Javier Gamo, F., Wyatt, P. G., Leroy, D., Siegl, P., Delves, M. J., Kyle, D. E., Wittlin, S., Marfurt, J., Price, R. N., Sinden, R. E., Winzeler, E. A., Charman, S. A., Bebrevska, L., Gray, D. W., Campbell, S., Fairlamb, A. H., Willis, P. A., Rayner, J. C., Fidock, D. A., Read,  K. D. & Gilbert, I. H.,, 2015, A novel multiple-stage antimalarial agent that inhibits protein synthesis, Nature 522, pp. 315-320

Hawkins, B.C., Lindqvist, L.M., Nhu, D.Q., Sharp, P.P., Segal, D., Powell, A.K., Campbell, M., Ryan, E., Chambers, J.M., White, J., Rizzacasa, M.A., Lessene, G., Huang, D.C., Burns, C.J., 2014, Simplified silvestrol analogues with potent cytotoxic activity, Chemmedchem [P], vol 9, issue 7, Wiley - V  C H Verlag GmbH & Co. KGaA, Weinheim Germany, pp. 1556-1566.

Ferrins, L., Rahmani, R.S., Sykes, M.L., Jones, A.J., Avery, V.M., Teston, E., Almohaywi, B., Yin, J., Smith, J., Chris, H., White, K.L., Ryan, E., Campbell, M., Charman, S.A., Kaiser, M., Baell, J.B., 2013, 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid  Trypanosoma brucei, the causative agent for human African trypanosomiasis, European Journal of Medicinal Chemistry [P], vol 66, Elsevier, Issy les Moulineaux France, pp. 450-465.

McCluskey, A., Daniel, J., Hadzic, G., Chau, N., Clayton, E.L., Mariana, A., Whiting, A., Gorgani, N.N., Lloyd, J., Quan, A., Moshkanbaryans, L., Krishnan, S., Perera, S., Chircop, M., von Kleist, L., McGeachie, A.B., Howes, M.T., Parton, R.G., Campbell, M., Sakoff, J.A., Wang, X., Sun, J., Robertson,  M., Deane, F.M., Nguyen, T.H., Meunier, F.A., Cousin, M.A., Robinson, P.J., 2013, Building a better dynasore: The dyngo compounds potently inhibit dynamin and endocytosis, Traffic [P], vol 14, issue 12, Wiley-Blackwell, Malden MA USA, pp. 1272-1289.

Murugesan, D., Mital, A., Kaiser, M., Shackleford, D., Morizzi, J., Katneni, K., Campbell, M., Hudson, A., Charman, S.A., Yeates, C., Gilbert, I.H., 2013, Discovery and structure-activity relationships of pyrrolone antimalarials, Journal of Medicinal Chemistry [P], vol 56, issue 7, ACS Publications,  Washington DC USA, pp. 2975-2990.

Keenan, M., Chaplin, J.H., Alexander, P.W., Abbott, M.J., Best, W.M., Khong, A., Botero, A., Perez, C., Cornwall, S., Thompson, R.C.A., White, K.L., Shackleford, D., Koltun, M., Chiu, F.C.K., Morizzi, J., Ryan, E., Campbell, M., von Geldern, T.W., Scandale, I., Chatelain, E., Charman, S.A., 2013, Two  analogues of fenarimol show curative activity in an experimental model of chagas disease, Journal of Medicinal Chemistry [P], vol 56, issue 24, ACS Publications, Washington DC USA, pp. 10158-10170.Charman, S., Arbe-Barnes, S., Bathurst, I., Brun, R., Campbell, M., Charman, W., Chiu, F., Chollet, J.,  Craft, C., Creek, D., Dong, Y., Matile, H., Maurer, M., Morizzi, J., Nguyen, T., Papastogiannidis, P., Scheurer, C., Shackleford, D., Sriraghavan, K., Stingelin, L., Tang, Y., Urwyler, H., Wang, X., White, K., Wittlin, S., Zhou, L., Vennerstrom, J., 2011, Synthetic ozonide drug candidate OZ439 offers  new hope for a single-dose cure of uncomplicated malaria, Proceedings Of The National Academy Of Sciences Of The United States Of America [P], vol 108, issue 11, National Academies Press, Washington D.C., USA, pp. 4400-4405.